SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
